Treatment progress of elderly acute myeloid leukemia:reports from the 57th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2016.02.005
- VernacularTitle:老年人急性髓系白血病治疗进展：第57届美国血液学会年会报道
- Author:
Huihui ZHAO
;
Sixuan QIAN
- Publication Type:Journal Article
- Keywords:
Leukemia,myeloid,acute;
Elderly;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2016;25(2):79-82
- CountryChina
- Language:Chinese
-
Abstract:
Elderly acute myeloid leukemia (AML) accounted for 35 % of all AML with the increased incidence year by year, and the median onset age is 67 years old. Generally, AML patients require strong chemotherapy, but older patients often cannot tolerate intense chemotherapy due to the viscera dysfunction. It is still lack of unified treatment clinically. Reports on treatment of elderly AML in the 57th American Society of Hematology (ASH) annual meeting covered multiple fields, in which the traditional induction chemotherapy, demethylation drug alone or in combination with other drugs, and novel drugs were an involved. This article reviewed the latest research on the elderly AML in the 57th ASH annual meeting.
